{"id":150099,"date":"2026-01-29T11:27:07","date_gmt":"2026-01-29T11:27:07","guid":{"rendered":"https:\/\/www.europesays.com\/se\/150099\/"},"modified":"2026-01-29T11:27:07","modified_gmt":"2026-01-29T11:27:07","slug":"comment-on-nosa-plugs-receiving-positive-organ-data-from-an-in-vivo-study","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/150099\/","title":{"rendered":"Comment on Nosa Plugs receiving positive organ data from an in vivo study"},"content":{"rendered":"

Nosa Plugs AB (\u201cNosa Plugs\u201d or \u201cthe Company\u201d) announced on 29 January 2026 that researchers at Lund University have published a scientific report showing that Nosa Plugs\u2019 intranasal drug delivery platform, Drug Delivery, achieves therapeutic drug levels in the brain. The results originate from the in vivo study completed during the summer of 2025 and indicate that NOSA Drug Delivery is an effective alternative to other routes of administration.<\/strong><\/p>\n

Analyst Group\u2019s view on the results<\/strong><\/p>\n

The in vivo study results published during the summer of 2025 involved releasing the drug Memantine, used in the treatment of Alzheimer\u2019s disease, via Nosa Plugs\u2019 technology platform. In the study, half of the recommended dose was administered, yet the results showed up to four times higher levels in blood plasma, corresponding to up to eight times higher uptake in blood plasma compared to the recommended dose. The findings therefore indicated that the drug is absorbed efficiently and that the same therapeutic effect may be achieved with a lower dose.<\/p>\n

The new organ data published on 29 January 2026 further confirms that Memantine has been effectively absorbed in the brain. This marks the first time Memantine has been released in gaseous form and demonstrated clinically relevant concentrations in brain tissue, indicating that the drug reached the brain efficiently. In addition, this serves as validation that NOSA Drug Delivery may represent a more effective alternative compared to other delivery methods such as tablets and injections.<\/p>\n

According to Analyst Group, Nosa Plugs\u2019 key competitive advantage in drug administration through its platform is that absorption can occur via the olfactory bulb, thereby enabling a direct effect on the central nervous system by bypassing the blood\u2013brain barrier. The blood\u2013brain barrier is a biological protective system that regulates which substances may pass from the bloodstream into the brain, which complicates delivery of drugs intended to treat conditions such as Alzheimer\u2019s disease or brain tumours. Against this backdrop, we see significant potential in Nosa Plugs\u2019 platform within drug administration, where the published organ data constitutes proof-of-concept that Nosa Plugs can function as an effective intranasal device for targeted drug delivery to the brain.<\/p>\n

Furthermore, the ability to achieve the same therapeutic effect with a lower dose through Nosa Plugs\u2019 technology platform compared to other delivery methods entails several advantages. A lower dose reduces treatment costs for both pharmaceutical companies and patients, enabling more cost-efficient therapy. In addition, potential side effects are expected to be lower at reduced doses, while also resulting in a lower climate footprint.<\/p>\n

The organ data constitutes an additional important proof-of-concept for NOSA Drug Delivery in the ongoing discussions with pharmaceutical companies regarding partnerships aimed at commercializing the Company\u2019s platform within drug administration. We expect the ongoing dialogues to involve pharmaceutical companies across multiple therapeutic areas, as previous tests have demonstrated that NOSA Drug Delivery can deliver drugs for the treatment of Alzheimer\u2019s disease, epilepsy, substance withdrawal and antidotes. Such a partnership is also expected to involve the pharmaceutical company financing further clinical studies required prior to commercialization of a drug using NOSA Drug Delivery as the delivery method. The Company had previously aimed to enter into a partnership during 2025; however, the Company has also stated that lead times in the industry are long. We expect the dialogues to continue and view the organ data as an additional important piece of evidence in these discussions.<\/p>\n

In summary,<\/strong> Analyst Group views the published organ data as a clear and important validation of Nosa Plugs\u2019 drug delivery platform, NOSA Drug Delivery. The results confirm that Memantine is not only absorbed efficiently in blood plasma but also achieves therapeutically relevant levels in brain tissue, thereby strengthening the evidence base that the platform may enable targeted drug delivery to the central nervous system by bypassing the blood\u2013brain barrier. In our view, this represents a meaningful proof-of-concept regarding the platform\u2019s effectiveness compared to traditional administration routes and its potential benefits in terms of reduced dose requirements. Overall, the organ data is expected to strengthen Nosa Plugs\u2019 position in ongoing discussions with pharmaceutical companies, where a partnership in turn is expected to finance the next steps in clinical development and, in the longer term, pave the way for commercialization of the Drug Delivery platform.<\/p>\n

Nosa Plugs AB (\u201dNosa Plugs\u201d eller \u201dBolaget\u201d) meddelade den 29 januari 2025 att forskare vid Lunds Universitet har publicerat en vetenskaplig rapport som visar att Nosa Plugs intranasala l\u00e4kemedelsplattform, Drug Delivery, uppm\u00e4ter terapeutiska niv\u00e5er av l\u00e4kemedel i hj\u00e4rnan<\/strong>. Resultaten kommer fr\u00e5n den in vivo-studien som slutf\u00f6rdes under sommaren \u00e5r 2025 och visar att NOSA Drug Delivery \u00e4r ett effektivt alternativ till andra administrationsv\u00e4gar. <\/strong><\/p>\n

Analyst Groups syn p\u00e5 resultaten<\/strong><\/p>\n

Resultaten fr\u00e5n in vivo-studien som publicerades under sommaren \u00e5r 2025 innebar att frisl\u00e4ppa l\u00e4kemedlet Memantin, som anv\u00e4nds mot Alzheimers sjukdom, genom Nosa Plugs teknologiplattform. I studien avgavs h\u00e4lften av rekommenderad dos men resultatet visade upp till fyra g\u00e5nger s\u00e5 h\u00f6g dos i blodplasma, vilket d\u00e4rmed inneb\u00e4r upp till \u00e5tta g\u00e5nger s\u00e5 h\u00f6gt upptag i blodplasma j\u00e4mf\u00f6rt med rekommenderad dos. S\u00e5ledes indikerade resultatet att l\u00e4kemedlet upptas p\u00e5 ett effektivt s\u00e4tt samt att samma effekt kan uppn\u00e5s med en l\u00e4gre dos l\u00e4kemedel.<\/p>\n

Den nya organdata som publicerades den 29 januari \u00e5r 2026 bekr\u00e4ftar vidare att Memantin har tagits upp effektivt i hj\u00e4rnan, vilket \u00e4r f\u00f6rsta g\u00e5ngen som Memantin har frisl\u00e4ppts i gasform och visat p\u00e5 kliniskt relevant koncentration i hj\u00e4rnv\u00e4vnad, n\u00e5got som p\u00e5visar att l\u00e4kemedlet har n\u00e5tt hj\u00e4rnan p\u00e5 ett effektivt s\u00e4tt. D\u00e4rtill inneb\u00e4r det en validering av att NOSA Drug Delivery antas vara ett mer effektivt alternativ j\u00e4mf\u00f6rt med andra distributionsmetoder som tabletter och injektioner.<\/p>\n

Nosa Plugs viktigaste konkurrensf\u00f6rdel avseende l\u00e4kemedelsadministration via Bolagets plattform \u00e4r enligt Analyst Group att upptag kan ske via luktbulben och d\u00e4rmed ge en direkt effekt mot det centrala nervsystemet genom att f\u00f6rbipassera blod-hj\u00e4rn-barri\u00e4ren. Blod-hj\u00e4rn-barri\u00e4ren \u00e4r ett biologiskt skyddssystem som reglerar vilka \u00e4mnen som f\u00e5r passera fr\u00e5n blodbanan in i hj\u00e4rnan, vilket f\u00f6rsv\u00e5rar att l\u00e4kemedel mot exempelvis Alzheimers eller hj\u00e4rntum\u00f6rer n\u00e5r hj\u00e4rnan. Givet detta ser vi stor potential i Nosa Plugs plattform inom l\u00e4kemedelsadministration, d\u00e4r den publicerade organdatan utg\u00f6r proof-of-concept att Nosa Plugs kan fungera som en effektiv intranasal anordning f\u00f6r riktad l\u00e4kemedelsleverans till hj\u00e4rnan.<\/p>\n

Vidare inneb\u00e4r det flera f\u00f6rdelar att en l\u00e4gre dos r\u00e4cker f\u00f6r att uppn\u00e5 samma effekt genom Nosa Plugs teknologiplattform j\u00e4mf\u00f6rt med andra distributionsmetoder. En l\u00e4gre dos medf\u00f6r en l\u00e4gre kostnad per behandling f\u00f6r s\u00e5v\u00e4l l\u00e4kemedelsbolag som patient, vilket \u00f6ppnar upp f\u00f6r en mer kostnadseffektiv behandling. Vidare f\u00f6rv\u00e4ntas potentiella biverkningar fr\u00e5n l\u00e4kemedel vara mindre vid l\u00e4gre dos, samtidigt som det medf\u00f6r l\u00e4gre klimatavtryck.<\/p>\n

Organdatan utg\u00f6r ytterligare ett viktigt proof-of-concept f\u00f6r NOSA Drug Delivery i diskussioner som f\u00f6rs med l\u00e4kemedelsbolag g\u00e4llande partnerskap f\u00f6r att kommersialisera Bolagets plattform inom l\u00e4kemedelsadministration. Vi f\u00f6rv\u00e4ntar oss att de p\u00e5g\u00e5ende dialogerna f\u00f6rs med l\u00e4kemedelsbolag inom flera olika omr\u00e5den, d\u00e5 tidigare tester har bevisat att NOSA Drug Delivery kan leverera l\u00e4kemedel f\u00f6r behandling av alzheimer, epilepsi, drogavv\u00e4njning samt antidoter. Ett s\u00e5dant partnerskap f\u00f6rv\u00e4ntas \u00e4ven inneb\u00e4ra att l\u00e4kemedelsbolaget finansierar vidare kliniska studier som kr\u00e4vs f\u00f6re en kommersialisering av ett l\u00e4kemedel med NOSA Drug Delivery som distributionsform. Bolaget hade som m\u00e5l att teckna ett partnerskap under \u00e5r 2025, samtidigt har Bolaget tidigare kommenterat att ledtider i branschen \u00e4r l\u00e5nga, vi f\u00f6rv\u00e4ntar oss att dialogerna fortg\u00e5r och att organdatan utg\u00f6r ytterligare en viktig pusselbit i dessa diskussioner.<\/p>\n

Sammanfattningsvis <\/strong>ser Analyst Group den publicerade organdatan som en tydlig och viktig validering av Nosa Plugs l\u00e4kemedelsplattform NOSA Drug Delivery. Resultaten bekr\u00e4ftar att Memantin inte bara tas upp effektivt i blodplasma, utan \u00e4ven uppn\u00e5r terapeutiskt relevanta niv\u00e5er i hj\u00e4rnv\u00e4vnad \u2013 vilket st\u00e4rker bevisl\u00e4get f\u00f6r att plattformen kan m\u00f6jligg\u00f6ra riktad l\u00e4kemedelsleverans till centrala nervsystemet genom att f\u00f6rbipassera blod-hj\u00e4rn-barri\u00e4ren. Detta inneb\u00e4r enligt oss ett betydelsefullt proof-of-concept, avseende plattformens effektivitet j\u00e4mf\u00f6rt med traditionella administrationsformer och dess potentiella f\u00f6rdelar i form av l\u00e4gre dosbehov. Sammantaget bed\u00f6ms organdatan st\u00e4rka Nosa Plugs position i p\u00e5g\u00e5ende dialoger med l\u00e4kemedelsbolag, d\u00e4r ett partnerskap i sin tur f\u00f6rv\u00e4ntas finansiera n\u00e4sta steg i den kliniska utvecklingen och p\u00e5 sikt bana v\u00e4g f\u00f6r kommersialisering av Drug Delivery-plattformen.<\/p>\n","protected":false},"excerpt":{"rendered":"Nosa Plugs AB (\u201cNosa Plugs\u201d or \u201cthe Company\u201d) announced on 29 January 2026 that researchers at Lund University…\n","protected":false},"author":2,"featured_media":75242,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[69],"tags":[113,112,34,31,33,32,30],"class_list":{"0":"post-150099","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-halsa","8":"tag-halsa","9":"tag-health","10":"tag-se","11":"tag-svenska","12":"tag-sverige","13":"tag-sweden","14":"tag-swedish"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/115978151153749429","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/150099","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=150099"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/150099\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/75242"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=150099"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=150099"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=150099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}